New obesity drug put to the heart test: no major risks found?
NCT ID NCT06200467
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This study checked whether survodutide, a new medicine for weight loss, causes any heart rhythm problems. About 110 adults with overweight or obesity received weekly injections of survodutide or a placebo for 30 weeks, along with occasional heart monitoring. The main goal was to see if the drug affects the heart's electrical activity, using moxifloxacin (a known heart-affecting drug) as a comparison. Results help ensure the drug is safe for the heart before further testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany
Conditions
Explore the condition pages connected to this study.